Can low‑dose naltrexone (LDN) be used to treat mast‑cell activation syndrome (MCAS), and what are the recommended dosing and safety considerations?

Low-Dose Naltrexone for MCAS: Not a Guideline-Supported Treatment

Low-dose naltrexone (LDN) is not included in the established treatment algorithm for mast cell activation syndrome (MCAS) according to the 2019 AAAAI guidelines, and should only be considered as an off-label experimental option after failure of guideline-directed therapies. 1

Guideline-Directed Treatment Algorithm for MCAS

The AAAAI Mast Cell Disorders Committee provides a clear hierarchical approach 1:

First-Line Therapies:

• H1 antihistamines (nonsedating preferred): fexofenadine or cetirizine at 2-4 times standard FDA-approved doses
• H2 antihistamines: famotidine or cimetidine for gastrointestinal symptoms and cardiovascular manifestations
• Cromolyn sodium (oral): reduces abdominal bloating, diarrhea, cramps; may help neuropsychiatric symptoms. Start low with divided dosing and titrate weekly upward

Second-Line Options:

• Leukotriene inhibitors (montelukast, zafirlukast, or zileuton): particularly if urinary LTE4 levels elevated
• Aspirin: for flushing/hypotension if urinary 11b-PGF2a elevated (up to 650 mg twice daily); contraindicated with NSAID sensitivity
• Doxepin: dual H1/H2 blocker for CNS manifestations (caution: cognitive decline risk in elderly, suicide risk in young adults with depression)

Refractory Disease:

• Steroid burst/taper: 0.5 mg/kg/day prednisone with slow taper over 1-3 months
• Omalizumab: case reports show prevention of anaphylactic episodes 1

Evidence for Low-Dose Naltrexone in MCAS

The evidence base is extremely limited and consists only of case reports and small retrospective reviews—no randomized controlled trials exist. 2, 3, 4

What the Research Shows:

A 2025 retrospective cohort of 93 chronic pain patients found that those with mast cell activation syndromes had the highest response rate to LDN (71.4%), though this represented a small subgroup 3. A 2018 case report described dramatic improvement in a patient with MCAS and POTS using LDN combined with IVIg and antibiotics for SIBO 2. A 2023 case report showed SIBO remission with LDN in a patient with suspected MCAS 4.

Critical limitations: These are uncontrolled observations without comparison groups, making it impossible to determine if improvements were due to LDN, natural disease fluctuation, or concurrent therapies.

Proposed Mechanism:

LDN (1-5 mg doses) transiently blocks opioid receptors, paradoxically increasing endorphin production. This theoretically upregulates regulatory T cells, reducing cytokine and antibody production 2, 5. However, this mechanism has not been validated in controlled studies for MCAS specifically.

Dosing Considerations (If Used Off-Label)

Important caveat: FDA-approved naltrexone dosing is 50 mg daily for alcohol/opioid dependence 6. Low-dose use (1-5 mg) is entirely off-label and requires compounding.

Typical off-label LDN regimen reported in literature:

• Start: 1-1.5 mg at bedtime
• Titrate: Increase by 0.5-1 mg every 1-2 weeks as tolerated
• Target: 3-4.5 mg daily (some use up to 5 mg)
• Timing: Usually taken at bedtime 3, 5

Safety Profile

Adverse effects in the 2025 retrospective review occurred in 49.5% of patients 3:

• Most common: nausea, fatigue
• No serious adverse effects reported
• Generally better tolerated than standard 50 mg naltrexone doses 5

Critical safety warnings from FDA labeling 6:

• Risk of hepatocellular injury, particularly with doses >50 mg (though LDN uses much lower doses)
• Must ensure patient is opioid-free for 7-10 days before initiation (risk of precipitated withdrawal)
• Contraindicated in patients currently using opioids for pain management

Practical Barriers

Access issues:

• LDN requires compounding pharmacy (not commercially available at low doses)
• Insurance typically does not cover off-label compounded medications
• Cost and availability vary significantly 5

Clinical Recommendation

If considering LDN for MCAS, this decision should only occur after:

1. Documented failure or intolerance of guideline-directed therapies (H1/H2 antihistamines, cromolyn sodium, leukotriene inhibitors) 1

2. Confirmation that patient is not using opioids and has no opioid dependence 6

3. Informed consent discussion acknowledging:

   • No controlled trials support this use
   • Evidence limited to case reports
   • This is experimental off-label therapy
   • May require out-of-pocket costs for compounding

4. Trial period of 2-3 months with objective symptom tracking before determining efficacy 3

The 2025 management yardstick for indolent mastocytosis and MCAS does not include LDN in its treatment algorithm 7, reinforcing that this remains an unproven therapy outside established standards of care.